TScan reports Q1 net loss $22.6M; Amgen partnership adds $30M upfront, extends cash runway

TScan Therapeutics, Inc.

2023-Q1 EPS reported -$0.93 revenue$6,803,000

Net loss $22.6M vs $16.2M in Q1 2022; revenue $6.8M, up from $3.0M on Novartis collaboration wind-down.
Amgen partnership for Crohn's disease targets: $30M upfront, potential milestones >$500M; cash runway extended into Q3 2024.
Phase 1 heme study: patients enrolled in all three arms; TSC-101 cleared for second dose level (two doses 40 days apart).
Cash and equivalents $95.6M at Mar 31, 2023; combined with Amgen upfront supports operations into Q3 2024.
Appointed Dr. Barbara Klencke to Board of Directors; she previously led oncology development at Sierra/GSK.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TScan Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.